TRAC team grows again

Cornwall-based regulatory affairs specialist appoints three new members of staff

Natalie Grogan, Debbie Finlay and Mike May have joined Cornwall's TRAC, which works with pharmaceutical companies to ensure that they are meeting their regulatory responsibilities.

Grogan takes the role of marketing manager, having relocated from Manchester where she has spent the last seven years in the marketing department of fashion and footwear home retailer JD Williams & Co.

Finlay and May boost TRAC’s Regulatory Affairs team, where they will be working on a range of projects for clients across Europe.

After spending 12 years living and working in Boston, US, Finlay returned to Cornwall in 2005 and graduated with a degree in Biological Science in 2009.

May graduated from Indiana State University in 2007 before relocating to study at the University of Plymouth where he gained a BSc in Human Biosciences.

‘We are delighted to have secured the services of Natalie, Debbie and Mike in the latest part of our development programme. They bring not only experience but also enthusiasm and a real desire to be part of the TRAC success story,’ said TRAC director Sarah Trethowan.

You may also like

Manufacturing

CARBOGEN AMCIS introduces SPRINT for early-phase development

A new, phase-appropriate approach designed to accelerate early-phase progression while maintaining scientific rigour
Manufacturing

How the QA and QP talent market is changing in pharma

Recruiting and retaining experienced quality and regulatory professionals has become significantly more complex for pharmaceutical and biotech companies
Regulatory

Andelyn Biosciences strengthens CDMO credentials with full ICMC certification

The certification received by Andelyn underscores their long-standing commitment to quality, operational readiness, and client service as the company supports innovators in advancing gene therapies from development through clinical and commercial manufacturing
Regulatory

MHRA approves beremagene geperpavec gene therapy gel for DEB from birth

The MHRA has approved beremagene geperpavec (Vyjuvek), a topical gene therapy gel for wounds in patients with dystrophic epidermolysis bullosa (DEB), for use from birth onwards
Regulatory

FDA approves AstraZeneca's FASENRA for hypereosinophilic syndrome

AstraZeneca's FASENRA has received FDA approval for hypereosinophilic syndrome in adults and adolescents aged 12 and above, based on Phase III NATRON trial data showing a 65% reduction in the risk of first HES flare compared to placebo
Manufacturing

Anxine responds to rising demand for integrated turnkey packaging solutions

Anxine has observed that more customers are moving away from purchasing individual machines and are instead choosing complete one-stop turnkey solutions that are easier to plan, manage, and put into operation
Regulatory

How the QA and QP Talent Market Is Changing in Pharma: Insights from Compliance Unlocked Podcast

Recruiting and retaining experienced quality and regulatory professionals has become significantly more complex for pharmaceutical and biotech companies
Subscribe now